Program OverviewThe Mastering Triglyceride Science: An In-Depth Master’s course is a master’s level course series addressing knowledge, competence, and practice gaps in managing hypertriglyceridemia and its associated pathophysiological manifestation and to provide lipid specialists with improved proficiency on the complexities of severe hypertriglyceridemia, and 
targets of therapy.

Target Audience
This activity is intended for lipidologists, allied health specialists, researchers, and other specialists with advanced knowledge and experience in preventive cardiology and/or lipid science.

Type of Activity
Live Course

Educational Objective(s)
At the conclusion of this activity, all participants should be able to:

• Describe the processes of triglyceride synthesis, secretion, and clearance.
• Identify key pharmaceutical targets for treatment in relation to disease management.
• Differentiate the clinical and genetic characteristics of Familial Chylomicronemia Syndrome (FCS), Multifactorial Chylomicronemia Syndrome (MCS), and Lipodystrophies.
• Evaluate existing and emerging evidence-based treatment options for hypertriglyceridemia, with a focus on pancreatitis risk reduction.
• Explain the mechanisms involved in hypertriglyceridemic pancreatitis and demonstrate the steps for accurate diagnosis and appropriate treatment.
• Assess the impact of remnant lipoproteins on ASCVD risk and develop management strategies based on current evidence.
• Identify dietary interventions tailored to specific triglyceride levels to optimize patient health and reduce cardiovascular or pancreatitis risk.
• Enhance the healthcare team's approach by applying insights from interactive case discussions and best practice sharing.

CRITERIA FOR SUCCESS
Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. Partial credit may be awarded for ACPE credit.  A statement of credit will be available upon completion of an online evaluation/claimed credit form at lipid.org/cme.  The deadline to claim credit is November 15, 2025. Questions related to this content should be sent to cme@lipid.org.

COMMERCIAL SUPPORT
This activity is supported by educational funding provided by Ionis Pharmaceuticals, Inc.

CREDIT DESIGNATION
CME/CE credit provided by the National Lipid Association

In support of improving patient care, The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Credit Designation Statement
The National Lipid Association designates this internet enduring activity for a maximum of 7.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Pharmacist Accreditation Statement
Universal Activity Number UAN JA0007192-0000-25-009-L01-P

This Activity has been approved for 7.5 contact hour(s) (0.75 CEUs) of the Accreditation Council for Pharmacy Education

Nursing
The maximum number of hours awarded for this CE activity is 7.5 contact hours.

Dieticians
Upon completion of the activity evaluation form, dietitians may submit evaluations of the quality of activities/materials to CDR. Poor evaluations of activities/materials may trigger an audit of the activities / materials by CDR.

DISCLOSURE INFORMATION
FACULTY, PLANNERS, & REVIEWERS

Elham Afghani, MD, MPH
Committee Member: Arrowhead Pharmaceuticals

Zahid Ahmad, MD, FNLA
Chair, Committee: Amyrt
Research: Ionis, NIH, US Department of Defense

Robert H. Eckel, MD, FAHA, FACC
Consultant: Amgen, 89Bio, Ionis, Madrigal, New Amsterdam, Precision BioSciences, Regeneron, The Healthy Aging Co.
Data and Safety Monitoring Board: Arrowhead
Advisory Board: Ionis
Expert Witness: Regeneron
Author: Up-To-Date

Abhimanyu Garg, MD
Consultant/research: Chiesi USA, Regeneron
Research: Intercept
Advisory Board: Zyelt Therapeutics

Nivedita Patni, MD
Advisory board: Chiesi, Ionis

Joseph Saseen, PharmD, CLS, MNLA
Committee Member: Amgen

Lauren Williams, MCN, RDN, LD
Speaker: Kaneka- Liposorber

Staff Disclosures

NLA Staff
Has nothing to disclose.  

DISCLOSURE OF UNLABELED USE AND INVESTIGATIONAL PRODUCTS
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLOSURE DECLARATION
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.    

DISCLAIMER
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

PERMISSIONS
The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.